Transcranial magnetic stimulation as a tool for understanding neurophysiology in Huntington's disease: A review

Neuroscience and Biobehavioral Reviews

Volumn 37, Issue 8, 2013, Pages 1420-1433

  Philpott, April L ^a   Fitzgerald, Paul B ^b   Cummins, Tarrant D R ^a   Georgiou Karistianis, Nellie ^a  

^a MONASH UNIVERSITY   (Australia)

^b Monash University and the Alfred ^*  (Australia)

Author keywords

Biomarker; Cortical inhibition; Corticostriatal circuitry; Electroencephalography; GABA; Huntington's disease; Transcranial magnetic stimulation

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; 4 AMINOBUTYRIC ACID B RECEPTOR; BIOLOGICAL MARKER;

ANATOMICAL VARIATION; BRAIN FUNCTION; COGNITION; DISEASE COURSE; ELECTROENCEPHALOGRAM; ENDOPHENOTYPE; ENZYME INHIBITION; EVENT RELATED POTENTIAL; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GABAERGIC TRANSMISSION; GENETICS; HUMAN; HUNTINGTON CHOREA; IMAGE ANALYSIS; MOTOR DYSFUNCTION; NERVE CELL NETWORK; NERVE EXCITABILITY; NERVOUS SYSTEM PARAMETERS; NEUROANATOMY; NEUROIMAGING; NEUROPATHOLOGY; NEUROPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; TRANSCRANIAL MAGNETIC STIMULATION;

BIOMARKER; CORTICAL INHIBITION; CORTICOSTRIATAL CIRCUITRY; ELECTROENCEPHALOGRAPHY; GABA; HUNTINGTON'S DISEASE; TRANSCRANIAL MAGNETIC STIMULATION;

BRAIN; DISEASE PROGRESSION; HUMANS; HUNTINGTON DISEASE; TRANSCRANIAL MAGNETIC STIMULATION;

EID: 84879702866     PISSN: 01497634     EISSN: 18737528     Source Type: Journal    
DOI: 10.1016/j.neubiorev.2013.05.009     Document Type: Review

References (278)

1. Abbruzzese G., Buccolieri A., Marchese R., Trompetto C., Mandich P., Schieppati M. Intracortical inhibition and facilitation are abnormal in Huntington's disease: a paired magnetic stimulation study. Neurosci. Lett. 1997, 228(2):87-90.
2. Abraham W.C. Metaplasticity: tuning synapses and networks for plasticity. Nat. Rev. Neurosci. 2008, 9(5). 387-387.
3. Albin R.L., Reiner A., Anderson K.D., Dure L.S., Handelin B., Balfour R., et al. Preferential loss of striato-external pallidal projection neurons in presymptomatic Huntington's disease. Ann. Neurol. 1992, 31(4):425-430.
4. Albin R.L., Young A.B., Penney J.B. The functional anatomy of basal ganglia disorders. Trends Neurosci. 1989, 12(10):366-375.
5. Alexander G.E., DeLong M.R., Strick P.L. Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Ann. Rev. Neurosci. 1986, 9:357-381.
6. Andrews T.C., Weeks R.A., Turjanski N., Gunn R.N., Watkins L.H.A., Sahakian B., et al. Huntington's disease progression. Brain 1999, 122(12):2353-2363.
7. Aron A.R., Schlaghecken F., Fletcher P.C., Bullmore E.T., Eimer M., Barker R., et al. Inhibition of subliminally primed responses is mediated by the caudate and thalamus: evidence from functional MRI and Huntington's disease. Brain 2003, 126(3):713-723.
8. Ashby P., Reynolds C., Wennberg R., Lozano A.M., Rothwell J. On the focal nature of inhibition and facilitation in the human motor cortex. Clin. Neurophysiol. 1999, 110(3):550-555.
9. Aylward E.H. Change in MRI striatal volumes as a biomarker in preclinical Huntington's disease. Brain Res. Bull. 2007, 72(2-3):152-158.
10. Aylward E.H., Nopoulos P.C., Ross C.A., Langbehn D.R., Pierson R.K., Mills J.A., et al. Longitudinal change in regional brain volumes in prodromal Huntington disease. J. Neurol. Neurosurg. Psychiatry 2011, 82(4):405-410.
11. Bamford K.A., Caine E.D., Kido D.K., Cox C., Shoulson I. A prospective evaluation of cognitive decline in early Huntington's disease: functional and radiographic correlates. Neurology 1995, 45(10):1867-1873.
12. Barker A.T., Jalinous R., Freeston I.L. Non-invasive magnetic stimulation of human motor cortex. Lancet 1985, 325(8437):1106-1107.
13. Bechtel N., Scahill R.I., Rosas H.D., Acharya T., Van Den Bogaard S.J.A., Jauffret C., et al. Tapping linked to function and structure in premanifest and symptomatic Huntington disease. Neurology 2010, 75(24):2150-2160.
14. Bentwich J., Dobronevsky E., Aichenbaum S., Shorer R., Peretz R., Khaigrekht M., et al. Beneficial effect of repetitive transcranial magnetic stimulation combined with cognitive training for the treatment of Alzheimer's disease: a proof of concept study. J. Neural. Transm. 2011, 118:463-471.
15. Berardelli A., Noth J., Thompson P.D., Bollen E.L.E.M., Currà A., Deuschl G., et al. Pathophysiology of chorea and bradykinesia in Huntington's disease. Mov. Disord. 1999, 14(3):398-403.
16. Beste C., Konrad C., Saft C., Ukas T., Andrich J., Pfleiderer B., et al. Alterations in voluntary movement execution in Huntington's disease are related to the dominant motor system - evidence from event-related potentials. Exp. Neurol. 2009, 216(1):148-157.
17. Beste C., Ness V., Falkenstein M., Saft C. On the role of fronto-striatal neural synchronization processes for response inhibition - evidence from ERP phase-synchronization analyses in pre-manifest Huntington's disease gene mutation carriers. Neuropsychologia 2011, 49(12):3484-3493.
18. Beste C., Saft C., Andrich J., Gold R., Falkenstein M. Error processing in Huntington's disease. PLoS ONE [Electronic Resource] 2006, 1(1):e86.
19. Beste C., Saft C., Güntürkün O., Falkenstein M. Increased cognitive functioning in symptomatic Huntington's disease as revealed by behavioral and event-related potential indices of auditory sensory memory and attention. J. Neurosci. 2008, 28(45):11695-11702.
20. Beste C., Wascher E., Dinse H.R., Saft C. Faster perceptual learning through excitotoxic neurodegeneration. Curr. Boil.: CB 2012, 22(20):1914-1917.
21. Bestmann S., Baudewig J., Siebner H.R., Rothwell J.C., Frahm J. Functional MRI of the immediate impact of transcranial magnetic stimulation on cortical and subcortical motor circuits. Eur. J. Neurosci. 2004, 19(7):1950-1962.
22. Biglan K.M., Ross C.A., Langbehn D.R., Aylward E.H., Stout J.C., Queller S., et al. Motor abnormalities in premanifest persons with Huntington's disease: the PREDICT-HD study. Mov. Disord. 2009, 24(12):1763-1772.
23. Bohanna I., Georgiou-Karistianis N., Egan G.F. Connectivity-based segmentation of the striatum in Huntington's disease: vulnerability of motor pathways. Neurobiol. Dis. 2011, 42(3):475-481.
24. Bohanna I., Georgiou-Karistianis N., Hannan A.J., Egan G.F. Magnetic resonance imaging as an approach towards identifying neuropathological biomarkers for Huntington's disease. Brain Res. Rev. 2008, 58(1):209-225.
25. Bohanna I., Georgiou-Karistianis N., Sritharan A., Asadi H., Johnston L., Churchyard A., et al. Diffusion Tensor Imaging in Huntington's disease reveals distinct patterns of white matter degeneration associated with motor and cognitive deficits. Brain Imaging Behav. 2011, 5(3):171-180.
26. Bonato C., Miniussi C., Rossini P.M. Transcranial magnetic stimulation and cortical evoked potentials: a TMS/EEG co-registration study. Clin. Neurophysiol. 2006, 117(8):1699-1707.
27. Brusa L., Versace V., Koch G., Bernardi G., Iani C., Stanzione P., et al. Improvement of choreic movements by 1Hz repetitive transcranial magnetic stimulation in Huntington's disease patients. Ann. Neurol. 2005, 58(4):655-656.
28. Burger J., Frank E., Kreuzer P., Kleinjung T., Vielsmeier V., Landgrebe M., et al. Transcranial magnetic stimulation for the treatment of tinnitus: 4-year follow-up in treatment responders - a retrospective analysis. Brain Stimulat. 2011, 4(4):222-227.
29. Cantello R. Applications of transcranial magnetic stimulation in movement disorders. J. Clin. Neurophysiol. 2002, 19(4):272-293.
30. Casarotto S., Romero Lauro L.J., Bellina V., Casali A.G., Rosanova M., Pigorini A., et al. EEG responses to TMS are sensitive to changes in the perturbation parameters and repeatable over time. PLoS ONE [Electronic Resource] 2010, 5(4):e10281.
31. Cash R.F.H., Ziemann U., Murray K., Thickbroom G.W. Late cortical disinhibition in human motor cortex: a triple-pulse transcranial magnetic stimulation study. J. Neurophysiol. 2010, 103(1):511-518.
32. Centonze D., Bernardi G., Koch G. Mechanisms of disease: basic-research-driven investigations in humans - the case of hyperkinetic disorders. Nat. Clin. Pract. Neurol. 2007, 3(10):572-580.
33. Centonze D., Rossi S., Prosperetti C., Tscherter A., Bernardi G., Maccarrone M., et al. Abnormal sensitivity to cannabinoid receptor stimulation might contribute to altered gamma-aminobutyric acid transmission in the striatum of R6/2 Huntington's disease mice. Biol. Psychiatry 2005, 57(12):1583-1589.
34. Cepeda C., Hurst R.S., Calvert C.R., Hernández-Echeagaray E., Nguyen O.K., Jocoy E., et al. Transient and progressive electrophysiological alterations in the corticostriatal pathway in a mouse model of Huntington's disease. J. Neurosci. 2003, 23(3):961-969.
35. Cepeda C., Starling A.J., Wu N., Nguyen O.K., Uzgil B., Soda T., et al. Increased GABAergic function in mouse models of Huntington's disease: reversal by BDNF. J. Neurosci. Res. 2004, 78(6):855-867.
36. Cepeda C., Wu N., André V.M., Cummings D.M., Levine M.S. The corticostriatal pathway in Huntington's disease. Prog. Neurobiol. 2007, 81(5-6):253-271.
37. Cha J.-H.J., Kosinski C.M., Kerner J.A., Alsdorf S.A., Mangiarini L., Davies S.W., et al. Altered brain neurotransmitter receptors in transgenic mice expressing a portion of an abnormal human Huntington disease gene. Proc. Natl. Acad. Sci. U. S. A. 1998, 95(11):6480-6485.
38. Cheeran B., Koch G., Stagg C.J., Baig F., Teo J. Transcranial magnetic stimulation: From neurophysiology to pharmacology, molecular biology and genomics. Neuroscientist 2010, 16(3):210-221.
39. Chen R. Interactions between inhibitory and excitatory circuits in the human motor cortex. Exp. Brain Res. 2004, 154(1):1-10.
40. Chen R., Classen J., Gerloff C., Celnik P., Wassermann E.M., Hallett M., et al. Depression of motor cortex excitability by low-frequency transcranial magnetic stimulation. Neurology 1997, 48(5):1398-1403.
41. Chen R., Cros D., Curra A., Di Lazzaro V., Lefaucheur J.P., Magistris M.R., et al. The clinical diagnostic utility of transcranial magnetic stimulation: report of an IFCN committee. Clin. Neurophysiol. 2008, 119(3):504-532.
42. Chu J., Gunraj C., Chen R. Possible differences between the time courses of presynaptic and postsynaptic GABAB mediated inhibition in the human motor cortex. Exp. Brain Res. 2008, 184(4):571-577.
43. Cotelli M., Manenti R., Cappa S.F., Geroldi C., Zanetti O., Rossini P.M., et al. Effect of transcranial magnetic stimulation on action naming in patients with Alzheimer disease. Arch. Neurol. 2006, 63(11):1602-1604.
44. Coxon J.P., Stinear C.M., Byblow W.D. Intracortical inhibition during volitional inhibition of prepared action. J. Neurophysiol. 2006, 95(6):3371-3383.
45. Crupi D., Ghilardi M.F., Mosiello C., Di Rocco A., Quartarone A., Battaglia F. Cortical and brainstem LTP-like plasticity in Huntington's disease. Brain Res. Bull. 2008, 75(1):107-114.
46. Cummings D.M., André V.M., Uzgil B.O., Gee S.M., Fisher Y.E., Cepeda C., et al. Alterations in cortical excitation and inhibition in genetic mouse models of Huntington's disease. J. Neurosci. 2009, 29(33):10371-10386.
47. Curra A., Modugno N., Inghilleri M., Manfredi M., Hallett M., Berardelli A. Transcranial magnetic stimulation techniques in clinical investigation. Neurology 2002, 59(12):1851-1859.
48. Daskalakis Z.J., Chen R. Evaluating the interaction between cortical inhibitory and excitatory circuits measured by TMS. The Oxford Handbook of Transcranial Magnetic Stimulation 2008, Oxford University Press, Oxford, UK. E.M. Wassermann, V. Walsh, C.M. Epstein, T. Paus, U. Ziemann, S.H. Lisanby (Eds.).
49. Daskalakis Z.J., Christensen B.J., Fitzgerald P.B., Roshan L., Chen R. The mechanisms of interhemispheric inhibition in the human motor cortex. J. Physiol. (Lond.) 2002, 543(1):317-326.
50. Daskalakis Z.J., Farzan F., Barr M.S., Maller J.J., Chen R., Fitzgerald P.B. Long-interval cortical inhibition from the dorsolateral prefrontal cortex: a TMS-EEG study. Neuropsychopharmacology 2008, 33(12):2860-2869.
51. Daskalakis Z.J., Farzan F., Barr M.S., Rusjan P.M., Favalli G., Levinson A.J., et al. Evaluating the relationship between long interval cortical inhibition, working memory and gamma band activity in the dorsolateral prefrontal cortex. Clin. EEG Neurosci. 2008, 39(3):150-155.
52. Daskalakis Z.J., Molnar G.F., Christensen B.K., Sailer A., Fitzgerald P.B., Chen R. An automated method to determine the transcranial magnetic stimulation-induced contralateral silent period. Clin. Neurophysiol. 2003, 114(5):938-944.
53. Davies C.H., Davies S.N., Collingridge G.L. Paired-pulse depression of monosynaptic GABA-mediated inhibitory postsynaptic responses in rat hippocampus. J. Physiol. (Lond.) 1990, 424(1):513-531.
54. Day B.L., Dressler D., Maertens De Noordhout A., Marsden C.D., Nakashima K., Rothwell J.C., et al. Electric and magnetic stimulation of human motor cortex: surface EMG and single motor unit responses. J. Physiol. (Lond.) 1989, 412:449-473.
55. De La Monte S.M.M.D.M.P.H., Vonsattel J.-P.M.D., Richardson E.P.J.M.D. Morphometric demonstration of atrophic changes in the cerebral cortex, white matter, and neostriatum in Huntington's disease. J. Neuropathol. Exp. Neurol. 1988, 47(5):516-525.
56. De Tommaso M., De Carlo F., Difruscolo O., Massafra R., Sciruicchio V., Bellotti R. Detection of subclinical brain electrical activity changes in Huntington's disease using artificial neural networks. Clin. Neurophysiol. 2003, 114(7):1237-1245.
57. De Tommaso M., Sciruicchio V., Specchio N., Difruscolo O., Vitale C., Specchio L.M., et al. Early modifications of auditory event-related potentials in carriers of the Huntington's disease gene. Acta Neurol. Belg. 2003, 103(4):192-198.
58. De Tommaso M., Sciruicchio V., Spinelli A., Specchio N., Difruscolo O., Puca F., et al. Features of the blink reflex in individuals at risk for Huntington's disease. Muscle Nerve 2001, 24(11):1520-1525.
59. Della Nave R., Ginestroni A., Tessa C., Giannelli M., Piacentini S., Filippi M., et al. Regional distribution and clinical correlates of white matter structural damage in Huntington disease: a tract-based spatial statistics study. AJNR Am. J. Neuroradiol. 2010, 31(9):1675-1681.
60. Di Lazzaro V., Oliviero A., Mazzone P., Pilato F., Saturno E., Insola A., et al. Direct demonstration of long latency cortico-cortical inhibition in normal subjects and in a patient with vascular Parkinsonism. Clin. Neurophysiol. 2002, 113(11):1673-1679.
61. Di Lazzaro V., Oliviero A., Profice P., Insola A., Mazzone P., Tonali P., et al. Direct demonstration of interhemispheric inhibition of the human motor cortex produced by transcranial magnetic stimulation. Exp. Brain Res. 1999, 124(4):520-524.
62. Di Lazzaro V., Restuccia D., Oliviero A., Profice P., Ferrara L., Insola A., et al. Magnetic transcranial stimulation at intensities below active motor threshold activates intracortical inhibitory circuits. Exp. Brain Res. 1998, 119(2):265-268.
63. Di Martino A., Scheres A., Margulies D.S., Kelly A.M.C., Uddin L.Q., Shehzad Z., et al. Functional connectivity of human striatum: a resting state fMRI study. Cereb. Cortex 2008, 18(12):2735-2747.
64. Diamond R., White R.F., Myers R.H., Mastromauro C., Koroshetz W.J., Butters N., et al. Evidence of presymptomatic cognitive decline in Huntington's disease. J. Clin. Exp. Neuropsychol. 1992, 14(6):961-975.
65. DiProspero N.A., Chen E., Vinod C., Plomann M., Kordower J.H., Tagle D.A. Early changes in Huntington's disease patient brains involve alterations in cytoskeletal and synaptic elements. Brain Cell Biol. 2004, 33(5):517-533.
66. Douaud G., Behrens T.E., Poupon C., Cointepas Y., Jbabdi S., Gaura V., et al. In vivo evidence for the selective subcortical degeneration in Huntington's disease. Neuroimage 2009, 46(4):958-966.
67. Duff K., Paulsen J.S., Mills J., Beglinger L.J., Moser D.J., Smith M.M., et al. Mild cognitive impairment in prediagnosed Huntington disease. Neurology 2010, 75(6):500-507.
68. Dumas E.M., Van Den Bogaard S.J.A., Ruber M.E., Reilmann R., Stout J.C., Craufurd D., et al. Early changes in white matter pathways of the sensorimotor cortex in premanifest Huntington's disease. Hum. Brain Mapp. 2012, 33(1):203-212.
69. Duncan C.C., Barry R.J., Connolly J.F., Fischer C., Michie P.T., Näätänen R., et al. Event-related potentials in clinical research: Guidelines for eliciting, recording, and quantifying mismatch negativity, P300, and N400. Clin. Neurophysiol. 2009, 120(11):1883-1908.
70. Edelmuth R.C.L., Nitsche M.A., Battistella L., Fregni F. Why do some promising brain-stimulation devices fail the next steps of clinical development?. Expert Rev. Med. Devices 2010, 7(1):67-97.
71. Ehle A.L., Stewart R.M., Lellelid N.A., Leventhal N.A. Evoked potentials in Huntington's disease: a comparative and longitudinal study. Arch. Neurol. 1984, 41(4):379-382.
72. Eisen A., Bohlega S., Bloch M., Hayden M. Silent periods, long-latency reflexes and cortical MEPs in Huntington's desease and at-risk relatives. Electroencephalogr. Clin. Neurophysiol. 1989, 74(6):444-449.
73. Esmaeilzadeh M., Ciarmiello A., Squitieri F. Seeking brain biomarkers for preventive therapy in Huntington disease. CNS Neurosci. Ther. 2011, 17(5):368-386.
74. Esser S.K., Huber R., Massimini M., Peterson M.J., Ferrarelli F., Tononi G. A direct demonstration of cortical LTP in humans: a combined TMS/EEG study. Brain Res. Bull. 2006, 69(1):86-94.
75. Farrow M., Chua P., Churchyard A., Bradshaw J.L., Chiu E., Georgiou-Karistianis N. Proximity to clinical onset influences motor and cognitive performance in presymptomatic Huntington disease gene carriers. Cogn. Behav. Neurol. 2006, 19(4):208-216.
76. Farrow M., Churchyard A., Chua P., Bradshaw J.L., Chiu E., Georgiou-Karistianis N. Attention, inhibition, and proximity to clinical onset in preclinical mutation carriers for Huntington's disease. J. Clin. Exp. Neuropsychol. 2007, 29(3):235-246.
77. Farzan F., Barr M.S., Levinson A.J., Chen R., Wong W., Fitzgerald P.B., et al. Reliability of long-interval cortical inhibition in healthy human subjects: a TMS-EEG study. J. Neurophysiol. 2010, 104(3):1339-1346.
78. Farzan F., Barr M.S., Wong W., Chen R., Fitzgerald P.B., Daskalakis Z.J. Suppression of [gamma]-oscillations in the dorsolateral prefrontal cortex following long interval cortical inhibition: a TMS-EEG study. Neuropsychopharmacology 2009, 34(6):1543-1551.
79. Feigin A., Leenders K.L., Moeller J.R., Missimer J., Kuenig G., Spetsieris P., et al. Metabolic network abnormalities in early Huntington's disease: an [(18)F]FDG PET study. J. Nucl. Med. 2001, 42(11):1591-1595.
80. Feigin A., Tang C., Ma Y., Mattis P., Zgaljardic D., Guttman M., et al. Thalamic metabolism and symptom onset in preclinical Huntington's disease. Brain 2007, 130(11):2858-2867.
81. Ferreri F., Pasqualetti P., Määttä S., Ponzo D., Ferrarelli F., Tononi G., et al. Human brain connectivity during single and paired pulse transcranial magnetic stimulation. Neuroimage 2011, 54(1):90-102.
82. Fielding J., Georgiou-Karistianis N., Bradshaw J., Millist L., Churchyard A., White O. Accelerated time-course of inhibition of return in Huntington's disease. Behav. Brain Res. 2006, 166(2):211-219.
83. Fisher R., Nakamura Y., Bestmann S., Rothwell J., Bostock H. Two phases of intracortical inhibition revealed by transcranial magnetic threshold tracking. Exp. Brain Res. 2002, 143(2):240-248.
84. Fitzgerald P.B. TMS-EEG: a technique that has come of age?. Clin. Neurophysiol. 2010, 121(3):265-267.
85. Fitzgerald P.B. The emerging use of brain stimulation treatments for psychiatric disorders. Aust. N. Z. J. Psychiatry 2011, 45(11):923-938.
86. Fitzgerald P.B., Brown T.L., Daskalakis Z.J. The application of transcranial magnetic stimulation in psychiatry and neurosciences research. Acta Psychiatr. Scand 2002, 105(5):324-340.
87. Fitzgerald P.B., Daskalakis Z.J., Hoy K., Farzan F., Upton D.J., Cooper N.R., et al. Cortical inhibition in motor and non-motor regions: a combined TMS-EEG study. Clin. EEG Neurosci. 2008, 39(3):112-117.
88. Fitzgerald P.B., Maller J.J., Hoy K., Farzan F., Daskalakis Z.J. GABA and cortical inhibition in motor and non-motor regions using combined TMS-EEG: a time analysis. Clin. Neurophysiol. 2009, 120(9):1706-1710.
89. Florian J., Müller-Dahlhaus M., Liu Y., Ziemann U. Inhibitory circuits and the nature of their interactions in the human motor cortex - a pharmacological TMS study. J. Physiol. (Lond.) 2008, 586(2):495-514.
90. Fregni F., Simon D.K., Wu A., Pascual-Leone A. Non-invasive brain stimulation for Parkinson's disease: a systematic review and meta-analysis of the literature. J. Neurol. Neurosurg. Psychiatry 2005, 76(12):1614-1623.
91. Freitas C., Fregni F., Pascual-Leone A. Meta-analysis of the effects of repetitive transcranial magnetic stimulation (rTMS) on negative and positive symptoms in schizophrenia. Schizophr. Res. 2009, 108(1-3):11-24.
92. Friedman D., Johnson R. Event-related potential (ERP) studies of memory encoding and retrieval: a selective review. Microsc. Res. Tech. 2000, 51(1):6-28.
93. Fuggetta G., Fiaschi A., Manganotti P. Modulation of cortical oscillatory activities induced by varying single-pulse transcranial magnetic stimulation intensity over the left primary motor area: a combined EEG and TMS study. Neuroimage 2005, 27(4):896-908.
94. Georgiou-Karistianis N. A peek inside the Huntington's brain: will functional imaging take us one step closer in solving the puzzle?. Exp. Neurol. 2009, 220(1,):5-8.
95. Georgiou-Karistianis N., Gray M.A., Domínguez D.J.F., Dymowski A.R., Bohanna I., Johnston L.A., et al. Automated differentiation of pre-diagnosis Huntington's disease from healthy control individuals based on quadratic discriminant analysis of the basal ganglia: the IMAGE-HD study. Neurobiol. Dis. 2013, 51:82-92.
96. Georgiou-Karistianis N., Scahill R.I., Tabrizi S.J., Squitieri F., Aylward E. Structural MRI in Huntington's disease and recommendations for its potential use in clinical trials. Neurosci. Biobehav. Rev. 2013, 37:480-490.
97. Georgiou-Karistianis N., Sritharan A., Farrow M., Cunnington R., Stout J.C., Bradshaw J., et al. Increased cortical recruitment in Huntington's disease using a Simon task. Neuropsychologia 2007, 45(8):1791-1800.
98. Georgiou N., Bradshaw J.L., Phillips J.G., Chiu E., Bradshaw J.A. Reliance on advance information and movement sequencing in Huntington's disease. Mov. Disord. 1995, 10(4):472-481.
99. Georgiou N., Phillips J.G., Bradshaw J.L., Cunnington R., Chiu E. Impairments of movement kinematics in patients with Huntington's disease: a comparison with and without a concurrent task. Mov. Disord. 1997, 12(3):386-396.
100. Golding C.V.P.P., Danchaivijitr C.M., Hodgson T.L.P., Tabrizi S.J.P.M., Kennard C.P.F. Identification of an oculomotor biomarker of preclinical Huntington disease. Neurology 2006, 67(3):485-487.
101. Gómez-Ansón B., Alegret M., Muñoz E., Monté G.C., Alayrach E., Sánchez A., et al. Prefrontal cortex volume reduction on MRI in preclinical Huntington's disease relates to visuomotor performance and CAG number. Parkinsonism Relat. Disord. 2009, 15(3):213-219.
102. Grafton S.T., Mazziotta J.C., Pahl J.J., George-Hyslop P.S., Haines J.L., Gusella J., et al. Serial changes of cerebral glucose metabolism and caudate size in persons at risk for Huntington's disease. Arch. Neurol. 1992, 49(11):1161-1167.
103. Gray M.A., Egan G.F., Ando A., Churchyard A., Chua P., Stout J.C., et al. Prefrontal activity in Huntington's disease reflects cognitive and neuropsychiatric disturbances: the IMAGE-HD study. Exp. Neurol. 2013, 239:218-228.
104. Hallett M. Transcranial magnetic stimulation and the human brain. Nature 2000, 406(6792):147-150.
105. Hallett M., Berardelli A. Movement disorders. The Oxford Handbook of Transcranial Magnetic Stimulation. 2008, Oxford University Press, Oxford, UK. E.M. Wassermann, E. Walsh, C.M. Epstein, T. Paus, U. Ziemann, S.H. Lisanby (Eds.).
106. Hanajima R., Ugawa Y. Paired-pulse measures. The Oxford Handbook of Transcranial Magnetic Stimulation. 2008, Oxford University Press, Oxford, UK. E.M. Wassermann, V. Walsh, C.M. Epstein, T. Paus, U. Ziemann, S.H. Lisanby (Eds.).
107. Hanajima R., Ugawa Y., Terao Y., Furubayashi T., Machii K., Shiio Y., et al. Intracortical inhibition of the motor cortex is normal in chorea. J. Neurol. Neurosurg. Psychiatry 1999, 66(6):783-786.
108. Hanajima R., Ugawa Y., Terao Y., Sakai K., Furubayashi T., Machii K., et al. Paired-pulse magnetic stimulation of the human motor cortex: differences among I waves. J. Physiol. (Lond.) 1998, 509(2):607-618.
109. Harrington D.L., Smith M.M., Zhang Y., Carlozzi N.E., Paulsen J.S. Cognitive domains that predict time to diagnosis in prodromal Huntington disease. J. Neurol. Neurosurg. Psychiatry 2012, 83(6):612-619.
110. Hodgson J.G., Agopyan N., Gutekunst C.-A., Leavitt B.R., LePiane F., Singaraja R., et al. A YAC mouse model for Huntington's disease with full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration. Neuron 1999, 23(1):181-192.
111. Hömberg V., Lange H.W. Central motor conduction to hand and leg muscles in Huntington's disease. Mov. Disord. 1990, 5(3):214-218.
112. Hoy K.E., Fitzgerald P.B. Brain stimulation in psychiatry and its effects on cognition. Nat. Rev. Neurol. 2010, 6(5). 267+.
113. Huntington's Disease Collaborative Research Group A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 1993, 72(6):971-983.
114. Huntington's Disease Collaborative Research Group Unified Huntington's disease rating scale: Reliability and consistency. Mov. Disord. 1996, 11(2):136-142.
115. Ilić T.V., Meintzschel F., Cleff U., Ruge D., Kessler K.R., Ziemann U. Short-interval paired-pulse inhibition and facilitation of human motor cortex: the dimension of stimulus intensity. J. Physiol. (Lond.) 2002, 545(1):153-167.
116. Ilmoniemi R.J., Kičić D. Methodology for combined TMS and EEG. Brain Topogr. 2010, 22(4):233-248.
117. Ilmoniemi R.J., Virtanen J., Ruohonen J., Karhu J., Aronen H.J., Näätänen R., et al. Neuronal responses to magnetic stimulation reveal cortical reactivity and connectivity. Neuroreport 1997, 8(16):3537-3540.
118. Inghilleri M., Berardelli A., Cruccu G., Manfredi M. Silent period evoked by transcranial stimulation of the human cortex and cervicomedullary junction. J. Physiol. (Lond.) 1993, 466:521-534.
119. Ives J.R., Rotenberg A., Poma R., Thut G., Pascual-Leone A. Electroencephalographic recording during transcranial magnetic stimulation in humans and animals. Clin. Neurophysiol. 2006, 117(8):1870-1875.
120. Joel D. Open interconnected model of basal ganglia-thalamocortical circuitry and its relevance to the clinical syndrome of Huntington's disease. Mov. Disord. 2001, 16(3):407-423.
121. Johnson S.A., Stout J.C., Solomon A.C., Langbehn D.R., Aylward E.H., Cruce C.B., et al. Beyond disgust: impaired recognition of negative emotions prior to diagnosis in Huntington's disease. Brain 2007, 130(7):1732-1744.
122. Jurgens C.K., Van De Wiel L., Van Es A.C.G.M., Grimbergen Y.M., Witjes-Ane M.-N.W., Van Der Grond J., et al. Basal ganglia volume and clinical correlates in 'preclinical' Huntington's disease. J. Neurol. 2008, 255(11):1785-1791.
123. Jurgens C.K., Van Der Hiele K., Reijntjes R.H.A.M., Van De Wiel L., Witjes-Ané M.N.W., Van Der Grond J., et al. Basal ganglia volume is strongly related to P3 event-related potential in premanifest Huntington's disease. Eur. J. Neurol. 2011, 18(8):1105-1108.
124. Kähkönen S., Komssi S., Wilenius J., Ilmoniemi R.J. Prefrontal TMS produces smaller EEG responses than motor-cortex TMS: implications for rTMS treatment in depression. Psychopharmacology (Berl.) 2005, 181(1):16-20.
125. Kähkönen S., Komssi S., Wilenius J., Ilmoniemi R.J. Prefrontal transcranial magnetic stimulation produces intensity-dependent EEG responses in humans. Neuroimage 2005, 24(4):955-960.
126. Kähkönen S., Wilenius J., Komssi S., Ilmoniemi R.J. Distinct differences in cortical reactivity of motor and prefrontal cortices to magnetic stimulation. Clin. Neurophysiol. 2004, 115(3):583-588.
127. Keck M.E., Welt T., Müller M.B., Erhardt A., Ohl F., Toschi N., et al. Repetitive transcranial magnetic stimulation increases the release of dopamine in the mesolimbic and mesostriatal system. Neuropharmacology 2002, 43(1):101-109.
128. Khedr E.M., Rothwell J.C., El-Atar A. One-year follow up of patients with chronic tinnitus treated with left temporoparietal rTMS. Eur. J. Neurol. 2009, 16(3):404-408.
129. Kirkwood S.C., Siemers E., Bond C., Conneally P.M., Christian J.C., Foroud T. Confirmation of subtle motor changes among presymptomatic carriers of the Huntington disease gene. Arch. Neurol. 2000, 57(7):1040-1044.
130. Kirkwood S.C., Siemers E., Hodes M.E., Conneally P.M., Christian J.C., Foroud T. Subtle changes among presymptomatic carriers of the Huntington's disease gene. J. Neurol. Neurosurg. Psychiatry 2000, 69(6):773-779.
131. Kirkwood S.C., Siemers E., Stout J.C., Hodes M.E., Conneally P.M., Christian J.C., et al. Longitudinal cognitive and motor changes among presymptomatic Huntington disease gene carriers. Arch. Neurol. 1999, 56(5):563-568.
132. Klapstein G.J., Fisher R.S., Zanjani H., Cepeda C., Jokel E.S., Chesselet M.-F., et al. Electrophysiological and morphological changes in striatal spiny neurons in R6/2 Huntington's disease transgenic mice. J. Neurophysiol. 2001, 86(6):2667-2677.
133. Klöppel S., Draganski B., Golding C.V., Chu C., Nagy Z., Cook P.A., et al. White matter connections reflect changes in voluntary-guided saccades in pre-symptomatic Huntington's disease. Brain 2008, 131(1):196-204.
134. Klöppel S., Draganski B., Siebner H.R., Tabrizi S.J., Weiller C., Frackowiak R.S.J. Functional compensation of motor function in pre-symptomatic Huntington's disease. Brain 2009, 132(6):1624-1632.
135. Koch G.M., Brusa L.M., Caltagirone C.M., Peppe A.M., Oliveri M.M., Stanzione P.M., et al. rTMS of supplementary motor area modulates therapy-induced dyskinesias in Parkinson disease. Neurology 2005, 65(4):623-625.
136. Komssi S., Aronen H.J., Huttunen J., Kesäniemi M., Soinne L., Nikouline V.V., et al. Ipsi- and contralateral EEG reactions to transcranial magnetic stimulation. Clin. Neurophysiol. 2002, 113(2):175-184.
137. Komssi S., Kähkönen S. The novelty value of the combined use of electroencephalography and transcranial magnetic stimulation for neuroscience research. Brain Res. Rev. 2006, 52(1):183-192.
138. Komssi S., Kähkönen S., Ilmoniemi R.J. The effect of stimulus intensity on brain responses evoked by transcranial magnetic stimulation. Hum. Brain Mapp. 2004, 21(3):154-164.
139. Krnjevic K. Role of GABA in cerebral cortex. Can. J. Physiol. Pharmacol. 1997, 75(5):439-451.
140. Kujirai T., Caramia M.D., Rothwell J.C., Day B.L., Thompson P.D., Ferbert A., et al. Corticocortical inhibition in human motor cortex. J. Physiol. (Lond.) 1993, 471:501-519.
141. Langbehn D.R., Brinkman R.R., Falush D., Paulsen J.S., Hayden M.R. A new model for prediction of the age of onset and penetrance for Huntington's disease based on CAG length. Clin. Genet. 2004, 65(4):267-277.
142. Lawrence A.D., Hodges J.R., Rosser A.E., Kershaw A., ffrench-Constant C., Rubinsztein D.C., et al. Evidence for specific cognitive deficits in preclinical Huntington's disease. Brain 1998, 121(7):1329-1341.
143. Lawrence A.D., Sahakian B.J., Robbins T.W. Cognitive functions and corticostriatal circuits: insights from Huntington's disease. Trends Cogn. Sci. 1998, 2(10):379-388.
144. Lawrence A.D., Weeks R.A., Brooks D.J., Andrews T.C., Watkins L.H.A., Harding A.E., et al. The relationship between striatal dopamine receptor binding and cognitive performance in Huntington's disease. Brain Cogn. 1998, 121:1343-1355.
145. Lefaucheur J.P. Repetitive transcranial magnetic stimulation (rTMS): insights into the treatment of Parkinson's disease by cortical stimulation. Clin. Neurophysiol. 2006, 36(3):125-133.
146. Lefaucheur J.P., Bachoud-Levi A.C., Bourdet C., Grandmougin T., Hantraye P., Cesaro P., et al. Clinical relevance of electrophysiological tests in the assessment of patients with Huntington's disease. Mov. Disord. 2002, 17(6):1294-1301.
147. Lefaucheur J.P., Drouot X., Von Raison F., Ménard-Lefaucheur I., Cesaro P., Nguyen J.-P. Improvement of motor performance and modulation of cortical excitability by repetitive transcranial magnetic stimulation of the motor cortex in Parkinson's disease. Clin. Neurophysiol. 2004, 115(11):2530-2541.
148. Lefaucheur J.P., Fénelon G., Ménard-Lefaucheur I., Wendling S., Nguyen J.P. Low-frequency repetitive TMS of premotor cortex can reduce painful axial spasms in generalized secondary dystonia: a pilot study of three patients. Clin. Neurophysiol. 2004, 34(3-4):141-145.
149. Lefaucheur J.P., Ménard-Lefaucheur I., Maison P., Baudic S., Cesaro P., Peschanski M., et al. Electrophysiological deterioration over time in patients with Huntington's disease. Mov. Disord. 2006, 21(9):1350-1354.
150. Lehéricy S., Bardinet E., Tremblay L., Van De Moortele P.-F., Pochon J.-B., Dormont D., et al. Motor control in basal ganglia circuits using fMRI and brain atlas approaches. Cereb. Cortex 2006, 16(2):149-161.
151. Lemiere J., Decruyenaere M., Evers-Kiebooms G., Vandenbussche E., Dom R. Cognitive changes in patients with Huntington's disease (HD) and asymptomatic carriers of the HD mutation: a longitudinal follow-up study. J. Neurol. 2004, 251:935-942.
152. Lorenzano C., Dinapoli L., Gilio F., Suppa A., Bagnato S., Currà A., et al. Motor cortical excitability studied with repetitive transcranial magnetic stimulation in patients with Huntington's disease. Clin. Neurophysiol. 2006, 117(8):1677-1681.
153. Maccabee P.J., Amassian V.E., Cracco R.Q., Rudell A., Eberle L. Suppression of letter recognition in humans with magnetic coil over occipital cortex. Electroencephalogr. Clin. Neurophysiol. 1990, 75(Supplement):S87.
154. Magnotta V., Kim J., Koscik T., Beglinger L., Espinso D., Langbehn D., et al. Diffusion Tensor Imaging in preclinical Huntington's disease. Brain Imaging Behav. 2009, 3(1):77-84.
155. Mäki H., Ilmoniemi R.J. The relationship between peripheral and early cortical activation induced by transcranial magnetic stimulation. Neurosci. Lett. 2010, 478(1):24-28.
156. Mally J., Stone T.W. Improvement in parkinsonian symptoms after repetitive transcranial magnetic stimulation. J. Neurol. Sci. 1999, 162(2):179-184.
157. Mascalchi M., Lolli F., Della Nave R., Tessa C., Petralli R., Gavazzi C., et al. Huntington disease: Volumetric, diffusion-weighted, and magnetization transfer MR imaging of brain. Radiology 2004, 232(3):867-873.
158. McClintock S.M., Freitas C., Oberman L., Lisanby S.H., Pascual-Leone A. Transcranial magnetic stimulation: a neuroscientific probe of cortical function in schizophrenia. Biol. Psychiatry 2011, 70(1):19-27.
159. McConnell K.A., Nahas Z., Shastri A., Lorberbaum J.P., Kozel F.A., Bohning D.E., et al. The transcranial magnetic stimulation motor threshold depends on the distance from coil to underlying cortex: a replication in healthy adults comparing two methods of assessing the distance to cortex. Biol. Psychiatry 2001, 49(5):454-459.
160. McDonnell M.N., Orekhov Y., Ziemann U. The role of GABAB receptors in intracortical inhibition in the human motor cortex. Exp. Brain Res. 2006, 173(1):86-93.
161. Medina F.J., Tunez I. Huntington's disease: the value of transcranial magnetic stimulation. Curr. Med. Chem. 2010, 17(23):2482-2491.
162. Miniussi C., Rossini P.M. Transcranial magnetic stimulation in cognitive rehabilitation. Neuropsychol. Rehabil. 2011, 21(5):579-601.
163. Miniussi C., Thut G. Combining TMS and EEG offers new prospects in cognitive neuroscience. Brain Topogr. 2010, 22(4):249-256.
164. Mockett B.G., Hulme S.R. Metaplasticity: new insights through electrophysiological investigations. J. Integr. Neurosci. 2008, 7(2):315-336.
165. Modugno N., Currà A., Giovannelli M., Priori A., Squitieri F., Ruggieri S., et al. The prolonged cortical silent period in patients with Huntington's disease. Clin. Neurophysiol. 2001, 112(8):1470-1474.
166. Münte T.F., Ridao-Alonso M.E., Preinfalk J., Jung A., Wieringa B.M., Matzke M., et al. An electrophysiological analysis of altered cognitive functions in Huntington disease. Arch. Neurol. 1997, 54(9):1089-1098.
167. Nahas Z., Lomarev M., Roberts D.R., Shastri A., Lorberbaum J.P., Teneback C., et al. Unilateral left prefrontal transcranial magnetic stimulation (TMS) produces intensity-dependent bilateral effects as measured by interleaved BOLD fMRI. Biol. Psychiatry 2001, 50(9):712-720.
168. Nakamura H., Kitagawa H., Kawaguchi Y., Tsuji H. Intracortical facilitation and inhibition after transcranial magnetic stimulation in conscious humans. J. Physiol. (Lond.) 1997, 498(3):817-823.
169. Nardone R., Lochner P., Marth R., Ausserer H., Bratti A., Tezzon F. Abnormal intracortical facilitation in early-stage Huntington's disease. Clin. Neurophysiol. 2007, 118(5):1149-1154.
170. Nguyen L., Bradshaw J.L., Stout J.C., Croft R.J., Georgiou-Karistianis N. Electrophysiological measures as potential biomarkers in Huntington's disease: review and future directions. Brain Res. Rev. 2010, 64(1):177-194.
171. Nikouline V.V., Ruohonen J., Ilmoniemi R.J. The role of the coil click in TMS assessed with simultaneous EEG. Clin. Neurophysiol. 1999, 110(8):1325-1328.
172. Nopoulos P.C., Aylward E.H., Ross C.A., Johnson H.J., Magnotta V.A., Juhl A.R., et al. Cerebral cortex structure in prodromal Huntington disease. Neurobiol. Dis. 2010, 40(3):544-554.
173. Orth M. Transcranial magnetic stimulation in Gilles de la Tourette syndrome. J. Psychosom. Res. 2009, 67(6):591-598.
174. Orth M., Rothwell J.C. The cortical silent period: Intrinsic variability and relation to the waveform of the transcranial magnetic stimulation pulse. Clin. Neurophysiol. 2004, 115(5):1076-1082.
175. Orth M., Schippling S., Schneider S.A., Bhatia K.P., Talelli P., Tabrizi S.J., et al. Abnormal motor cortex plasticity in premanifest and very early manifest Huntington disease. J. Neurol. Neurosurg. Psychiatry 2010, 81(3):267-270.
176. Orth M., Snijders A.H., Rothwell J.C. The variability of intracortical inhibition and facilitation. Clin. Neurophysiol. 2003, 114(12):2362-2369.
177. Painold A., Anderer P., Holl A.K., Letmaier M., Saletu-Zyhlarz G.M., Saletu B., et al. Comparative EEG, mapping studies in Huntington's disease patients and controls. J. Neural Transm. 2010, 117(11):1307-1318.
178. Painold A., Anderer P., Holl A.K., Letmaier M., Saletu-Zyhlarz G.M., Saletu B., et al. EEG low-resolution brain electromagnetic tomography (LORETA) in Huntington's disease. J. Neurol. 2011, 258(5):840-854.
179. Papp K.V., Kaplan R.F., Snyder P.J. Biological markers of cognition in prodromal Huntington's disease: a review. Brain Cogn. 2011, 77(2):280-291.
180. Parent A., Hazrati L.-N. Functional anatomy of the basal ganglia. I. The cortico-basal ganglia-thalamo-cortical loop. Brain Res. Rev. 1995, 20(1):91-127.
181. Pascual-Leone A., Freitas C., Oberman L., Horvath J., Halko M., Eldaief M., et al. Characterizing brain cortical plasticity and network dynamics across the age-span in health and disease with TMS-EEG and TMS-fMRI. Brain Topogr. 2011, 24(3):302-315.
182. Pascual-Leone A., Walsh V., Rothwell J. Transcranial magnetic stimulation in cognitive neuroscience - virtual lesion, chronometry, and functional connectivity. Curr. Opin. Neurobiol. 2000, 10(2):232-237.
183. Paulsen J.S. Functional imaging in Huntington's disease. Exp. Neurol. 2009, 216(2):272-277.
184. Paulsen J.S. Early detection of Huntington's disease. Future Neurol. 2010, 5(1):85-104.
185. Paulsen J.S., Hayden M., Stout J.C., Langbehn D.R., Aylward E.H., Ross C.A., et al. Preparing for preventive clinical trials: the Predict-HD study. Arch. Neurol. 2006, 63(6):883-890.
186. Paulsen J.S., Langbehn D.R., Stout J.C., Aylward E.H., Ross C.A., Nance M., et al. Detection of Huntington's disease decades before diagnosis: the Predict-HD study. J. Neurol. Neurosurg. Psychiatry 2008, 79(8):874-880.
187. Paulsen J.S., Nopoulos P.C., Aylward E.H., Ross C.A., Johnson H., Magnotta V.A., et al. Striatal and white matter predictors of estimated diagnosis for Huntington disease. Brain Res. Bull. 2010, 82(3-4):201-207.
188. Paulsen J.S., Zhao H., Stout J.C., Brinkman R.R., Guttman M., Ross C.A., et al. Clinical markers of early disease in persons near onset of Huntington's disease. Neurology 2001, 57(4):658-662.
189. Paulsen J.S., Zimbelman J.L., Hinton S.C., Langbehn D.R., Leveroni C.L., Benjamin M.L., et al. fMRI biomarker of early neuronal dysfunction in presymptomatic Huntington's disease. AJNR Am. J. Neuroradiol. 2004, 25(10):1715-1721.
190. Paus T., Barrett J. Transcranial magnetic stimulation (TMS) of the human frontal cortex: implications for repetitive TMS treatment of depression. J. Psychiatry Neurosci. 2004, 29(4):268-279.
191. Paus T., Castro-Alamancos M.A., Petrides M. Cortico-cortical connectivity of the human mid-dorsolateral frontal cortex and its modulation by repetitive transcranial magnetic stimulation. Eur. J. Neurosci. 2001, 14(8):1405-1411.
192. Paus T., Sipila P.K., Strafella A.P. Synchronization of neuronal activity in the human primary motor cortex by transcranial magnetic stimulation: an EEG study. J. Neurophysiol. 2001, 86(4):1983-1990.
193. Penney J.B., Young A.B., Shoulson I., Starosta-Rubenstein S., Snodgrass S.R., Sanchez-Ramos J., et al. Huntington's disease in Venezuela: 7 years of follow-up on symptomatic and asymptomatic individuals. Mov. Disord. 1990, 5(2):93-99.
194. Pillai J.A., Hansen L.A., Masliah E., Goldstein J.L., Edland S.D., Corey-Bloom J. Clinical severity of Huntington's disease does not always correlate with neuropathologic stage. Mov. Disord. 2012, 27(9):1099-1103.
195. Priori A., Berardelli A., Inghilleri M., Polidori L., Manfredi M. Electromyographic silent period after transcranial brain stimulation in Huntington's disease. Mov. Disord. 1994, 9(2):178-182.
196. Priori A., Polidori L., Rona S., Manfredi M., Berardelli A. Spinal and cortical inhibition in Huntington's chorea. Mov. Disord. 2000, 15(5):938-946.
197. Reading S.A.J., Yassa M.A., Bakker A., Dziorny A.C., Gourley L.M., Yallapragada V., et al. Regional white matter change in pre-symptomatic Huntington's disease: a diffusion tensor imaging study. Psychiatry Res. 2005, 140(1):55-62.
198. Reithler J., Peters J.C., Sack A.T. Multimodal transcranial magnetic stimulation: using concurrent neuroimaging to reveal the neural network dynamics of noninvasive brain stimulation. Prog. Neurobiol. 2011, 94(2):149-165.
199. Ridding M.C., Rothwell J.C. Is there a future for therapeutic use of transcranial magnetic stimulation?. Nat. Rev. Neurosci. 2007, 8(7):559-567.
200. Ridding M.C., Rothwell J.C., Inzelberg R. Changes in excitability of motor cortical circuitry in patients with Parkinson's disease. Ann. Neurol. 1995, 37(2):181-188.
201. Rizk-Jackson A., Stoffers D., Sheldon S., Kuperman J., Dale A., Goldstein J., et al. Evaluating imaging biomarkers for neurodegeneration in pre-symptomatic Huntington's disease using machine learning techniques. Neuroimage 2011, 56(2):788-796.
202. Robertson E.M., Théoret H., Pascual-Leone A. Studies in cognition: the problems solved and created by transcranial magnetic stimulation. J. Cogn. Neurosci. 2003, 15(7):948-960.
203. Rosas H.D., Hevelone N.D., Zaleta A.K., Greve D.N., Salat D.H., Fischl B. Regional cortical thinning in preclinical Huntington disease and its relationship to cognition. Neurology 2005, 65:745-747.
204. Rosas H.D., Liu A.K., Hersch S.M., Glessner M., Ferrante R.J., Salat D.H., et al. Regional and progressive thinning of the cortical ribbon in Huntington's disease. Neurology 2002, 58(5):695-701.
205. Rosas H.D., Reuter M., Doros G., Lee S.Y., Triggs T., Malarick K., et al. A tale of two factors: what determines the rate of progression in Huntington's disease? A longitudinal MRI study. Mov. Disord. 2011, 26(9):1691-1697.
206. Rosas H.D., Salat D.H., Lee S.Y., Zaleta A.K., Hevelone N., Hersch S.M. Complexity and heterogeneity: what drives the ever-changing brain in Huntington's disease?. Ann. N. Y. Acad. Sci. 2008, 1147(1):196-205.
207. Rosas H.D., Salat D.H., Lee S.Y., Zaleta A.K., Pappu V., Fischl B., et al. Cerebral cortex and the clinical expression of Huntington's disease: complexity and heterogeneity. Brain 2008, 131(4):1057-1068.
208. Rosas H.D., Tuch D.S., Hevelone N.D., Zaleta A.K., Vangel M., Hersch S.M., et al. Diffusion tensor imaging in presymptomatic and early Huntington's disease: selective white matter pathology and its relationship to clinical measures. Mov. Disord. 2006, 21(9):1317-1325.
209. Rosenberg N.K., Sørensen S.A., Christensen A.L. Neuropsychological characteristics of Huntington's disease carriers: a double blind study. J. Med. Genet. 1995, 32(8):600-604.
210. Roshan L., Paradiso G.O., Chen R. Two phases of short-interval intracortical inhibition. Exp. Brain Res. 2003, 151(3):330-337.
211. Rösler K.M., Magistris M.R. The size of motor evoked potentials: influencing parameters and quantification. The Oxford Handbook of Transcranial Magnetic Stimulation. 2008, Oxford University Press, Oxford, UK. E.M. Wassermann, V. Walsh, C.M. Epstein, T. Paus, U. Ziemann, S.H. Lisanby (Eds.).
212. Rossi S., Hallett M., Rossini P.M., Pascual-Leone A. Safety, ethical considerations, and application guidelines for the use of transcranial magnetic stimulation in clinical practice and research. Clin. Neurophysiol. 2009, 120(12):2008-2039.
213. Rossi S., Pasqualetti P., Rossini P.M., Feige B., Ulivelli M., Glocker F.X., et al. Effects of repetitive transcranial magnetic stimulation on movement-related cortical activity in humans. Cereb. Cortex 2000, 10(8):802-808.
214. Rossini P.M., Barker A.T., Berardelli A., Caramia M.D., Caruso G., Cracco R.Q., et al. Non-invasive electrical and magnetic stimulation of the brain, spinal cord and roots: basic principles and procedures for routine clinical application. Report of an IFCN committee. Electroencephalogr. Clin. Neurophysiol. 1994, 91(2):79-92.
215. Rowe K.C., Paulsen J.S., Langbehn D.R., Duff K., Beglinger L.J., Wang C., et al. Self-paced timing detects and tracks change in prodromal Huntington disease. Neuropsychology 2010, 24(4):435-442.
216. Rupp J., Blekher T., Jackson J., Beristain X., Marshall J., Hui S., et al. Progression in prediagnostic Huntington disease. J. Neurol. Neurosurg. Psychiatry 2010, 81(4):379-384.
217. Sack A.T., Linden D.E.J. Combining transcranial magnetic stimulation and functional imaging in cognitive brain research: possibilities and limitations. Brain Res. Rev. 2003, 43(1):41-56.
218. Saft C., Schüttke A., Beste C., Andrich J., Heindel W., Pfleiderer B. fMRI reveals altered auditory processing in manifest and premanifest Huntington's disease. Neuropsychologia 2008, 46(5):1279-1289.
219. Saint-Cyr J.A. Frontal-striatal circuit functions: context, sequence, and consequence. J. Int. Neuropsychol. Soc. 2003, 9(01):103-128.
220. Sánchez-Castañeda C., Cherubini A., Elifani F., Péran P., Orobello S., Capelli G., et al. Seeking Huntington disease biomarkers by multimodal, cross-sectional basal ganglia imaging. Hum. Brain Mapp. 2012.
221. Sanger T.D., Garg R.R., Chen R. Interactions between two different inhibitory systems in the human motor cortex. J. Physiol. (Lond.) 2001, 530(2):307-317.
222. Sapp E., Schwarz C., Chase K., Bhide P.G., Young A.B., Penney J., et al. Huntingtin localization in brains of normal and Huntington's disease patients. Ann. Neurol. 1997, 42(4):604-612.
223. Sasaki H., Masumoto J., Inui N. Effects of aging on control of timing and force of finger tapping. Motor Control 2011, 15(2):175-186.
224. Schippling S., Schneider S.A., Bhatia K.P., Münchau A., Rothwell J.C., Tabrizi S.J., et al. Abnormal motor cortex excitability in preclinical and very early Huntington's disease. Biol. Psychiatry 2009, 65(11):959-965.
225. Schneider S.A., Wilkinson L., Bhatia K.P., Henley S.M.D., Rothwell J.C., Tabrizi S.J., et al. Abnormal explicit but normal implicit sequence learning in premanifest and early Huntington's disease. Mov. Disord. 2010, 25(10):1343-1349.
226. Shang H., Danek A., Landwehrmeyer B., Burgunder J.-M. Huntington's disease: new aspects on phenotype and genotype. Parkinsonism Relat. Disord. 2012, 18(Supplement 1):S107-S109.
227. Siebner H.R., Bergmann T.O., Bestmann S., Massimini M., Johansen-Berg H., Mochizuki H., et al. Consensus paper: combining transcranial stimulation with neuroimaging. Brain Stimulat. 2009, 2(2):58-80.
228. Siebner H.R., Dressnandt J., Auer C., Conrad B. Continuous intrathecal baclofen infusions induced a marked increase of the transcranially evoked silent period in a patient with generalized dystonia. Muscle Nerve 1998, 21(9):1209-1212.
229. Siebner H.R., Rossmeier C., Mentschel C., Peinemann A., Conrad B. Short-term motor improvement after sub-threshold 5-Hz repetitive transcranial magnetic stimulation of the primary motor hand area in Parkinson's disease. J. Neurol. Sci. 2000, 178(2):91-94.
230. Snowden J.S., Craufurd D., Thompson J., Neary D. Psychomotor, executive, and memory function in preclinical Huntington's disease. J. Clin. Exp. Neuropsychol. 2002, 24(2):133-145.
231. Solomon A.C., Stout J.C., Weaver M., Queller S., Tomusk A., Whitlock K.B., et al. Ten-year rate of longitudinal change in neurocognitive and motor function in prediagnosis Huntington disease. Mov. Disord. 2008, 23(13):1830-1836.
232. Speer A.M., Willis M.W., Herscovitch P., Daube-Witherspoon M., Repella Shelton J., Benson B.E., et al. Intensity-dependent regional cerebral blood flow during 1-Hz repetitive transcranial magnetic stimulation (rTMS) in healthy volunteers studied with H215O positron emission tomography: I. Effects of primary motor cortex rTMS. Biol. Psychiatry 2003, 54(8):818-825.
233. Sritharan A., Egan G.F., Johnston L., Horne M., Bradshaw J.L., Bohanna I., et al. A longitudinal diffusion tensor imaging study in symptomatic Huntington's disease. J. Neurol. Neurosurg. Psychiatry 2010, 81(3):257-262.
234. Stagg C.J., Wylezinska M., Matthews P.M., Johansen-Berg H., Jezzard P., Rothwell J.C., et al. Neurochemical effects of theta burst stimulation as assessed by magnetic resonance spectroscopy. J. Neurophysiol. 2009, 101(6):2872-2877.
235. Stewart L.M., Walsh V., Rothwell J.C. Motor and phosphene thresholds: a transcranial magnetic stimulation correlation study. Neuropsychologia 2001, 39(4):415-419.
236. Stinear C.M., Byblow W.D. Elevated threshold for intracortical inhibition in focal hand dystonia. Mov. Disord. 2004, 19(11):1312-1317.
237. Stinear C.M., Byblow W.D. Impaired modulation of intracortical inhibition in focal hand dystonia. Cereb. Cortex 2004, 14(5):555-561.
238. Stoffers D., Sheldon S., Kuperman J., Goldstein J.M., Corey-Bloom J., Aron A.R. Contrasting gray and white matter changes in preclinical Huntington disease: an MRI study. Neurology 2010, 74(15):1208-1216.
239. Storey E., Kowall N.W., Finn S.F., Mazurek M.F., Beal M.F. The cortical lesion of Huntington's disease: further neurochemical characterization, and reproduction of some of the histological and neurochemical features by N-methyl-d-aspartate lesions of rat cortex. Ann. Neurol. 1992, 32(4):526-534.
240. Stout J.C., Jones R., Labuschagne I., O'Regan A.M., Say M.J., Dumas E.M., et al. Evaluation of longitudinal 12 and 24 month cognitive outcomes in premanifest and early Huntington's disease. J. Neurol. Neurosurg. Psychiatry 2012, 83(7):687-694.
241. Stout J.C., Paulsen J.S., Queller S., Solomon A.C., Whitlock K.B., Campbell J.C., et al. Neurocognitive signs in prodromal Huntington disease. Neuropsychology 2011, 25(1):1-14.
242. Strafella A.P., Paus T. Cerebral blood-flow changes induced by paired-pulse transcranial magnetic stimulation of the primary motor cortex. J. Neurophysiol. 2001, 85(6):2624-2629.
243. Strafella A.P., Paus T., Barrett J., Dagher A. Repetitive transcranial magnetic stimulation of the human prefrontal cortex induces dopamine release in the caudate nucleus. J. Neurosci. 2001, 21(15):RC157.
244. Strafella A.P., Paus T., Fraraccio M., Dagher A. Striatal dopamine release induced by repetitive transcranial magnetic stimulation of the human motor cortex. Brain 2003, 126(12):2609-2615.
245. Strafella A.P., Van Der Werf Y.D., Sadikot A.F. Transcranial magnetic stimulation of the human motor cortex influences the neuronal activity of subthalamic nucleus. Eur. J. Neurosci. 2004, 20(8):2245-2249.
246. Swerdlow N.R., Paulsen J.S., Braff D.L., Butters N., Geyer M.A., Swenson M.R. Impaired prepulse inhibition of acoustic and tactile startle responses in patients with Huntington's disease. J. Neurol. Neurosurg. Psychiatry 1995, 58:192-200.
247. Tabrizi S.J., Langbehn D.R., Leavitt B.R., Roos R.A.C., Durr A., Craufurd D., et al. Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data. Lancet Neurol. 2009, 8(9):791-801.
248. Tabrizi S.J., Reilmann R., Roos R.A.C., Durr A., Leavitt B., Owen G., et al. Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24 month observational data. Lancet Neurol. 2012, 11(1):42-53.
249. Tabrizi S.J., Scahill R.I., Durr A., Roos R.A.C., Leavitt B.R., Jones R., et al. Biological and clinical changes in premanifest and early stage Huntington's disease in the TRACK-HD study: the 12-month longitudinal analysis. Lancet Neurol. 2011, 10(1):31-42.
250. Taylor P.C.J., Walsh V., Eimer M. Combining TMS and EEG to study cognitive function and cortico-cortico interactions. Behav. Brain Res. 2008, 191(2):141-147.
251. Tegenthoff M., Vorgerd M., Juskowiak F., Roos V., Malin J.P. Postexcitatory inhibition after transcranial magnetic single and double brain stimulation in Huntington's disease. Electroencephalogr. Clin. Neurophysiol. 1996, 101(4):298-303.
252. Thieben M.J., Duggins A.J., Good C.D., Gomes L., Mahant N., Richards F., et al. The distribution of structural neuropathology in pre-clinical Huntington's disease. Brain 2002, 125(8):1815-1828.
253. Thiruvady D.R., Georgiou-Karistianis N., Egan G.F., Ray S., Sritharan A., Farrow M., et al. Functional connectivity of the prefrontal cortex in Huntington's disease. J. Neurol. Neurosurg. Psychiatry 2007, 78(2):127-133.
254. Thut G., Ives J.R., Kampmann F., Pastor M.A., Pascual-Leone A. A new device and protocol for combining TMS and online recordings of EEG and evoked potentials. J. Neurosci. Methods 2005, 141(2):207-217.
255. Thut G., Pascual-leone A. Integrating TMS with EEG: How and what for?. Brain Topogr. 2010, 22(4):215-218.
256. Tiitinen H., Virtanen J., Ilmoniemi R.J., Kamppuri J., Ollikainen M., Ruohonen J., et al. Separation of contamination caused by coil clicks from responses elicited by transcranial magnetic stimulation. Clin. Neurophysiol. 1999, 110(5):982-985.
257. Unschuld P.G., Joel S.E., Liu X., Shanahan M., Margolis R.L., Biglan K.M., et al. Impaired cortico-striatal functional connectivity in prodromal Huntington's disease. Neurosci. Lett. 2012, 514(2):204-209.
258. Van Der Hiele K., Jurgens C.K., Vein A.A., Reijntjes R.H.A.M., Witjes-Ané M.-N.W., Roos R.A.C., et al. Memory activation reveals abnormal EEG in preclinical Huntington's disease. Mov. Disord. 2007, 22(5):690-695.
259. Van Der Werf Y.D., Paus T. The neural response to transcranial magnetic stimulation of the human motor cortex. I. Intracortical and cortico-cortical contributions. Exp. Brain Res. 2006, 175(2):231-245.
260. Virtanen J., Ruohonen J., Näätänen R., Ilmoniemi R.J. Instrumentation for the measurement of electric brain responses to transcranial magnetic stimulation. Med. Biol. Eng. Comput. 1999, 37(3):322-326.
261. Vonsattel J.P., DiFiglia M. Huntington disease. J. Neuropathol. Exp. Neurol. 1998, 57(5):369-384.
262. Wagner T., Valero-Cabre A., Pascual-Leone A. Noninvasive human brain stimulation. Annu. Rev. Biomed. Eng. 2007, 9(1):527-565.
263. Walsh V., Rushworth M.F. A primer of magnetic stimulation as a tool for neuropsychology. Neuropsychologia 1999, 37(2):125-135.
264. Ward J., Sheppard J., Shpritz B., Margolis R.L., Rosenblatt A., Brandt J. A four-year prospective study of cognitive functioning in Huntington's disease. J. Int. Neuropsychol. Soc. 2006, 12(04):445-454.
265. Weaver K.E., Richards T.L., Liang O., Laurino M.Y., Samii A., Aylward E.H. Longitudinal diffusion tensor imaging in Huntington's disease. Exp. Neurol. 2009, 216(2):525-529.
266. Weir D.W., Sturrock A., Leavitt B.R. Development of biomarkers for Huntington's disease. Lancet Neurol. 2011, 10(6):573-590.
267. Werhahn K.J., Kunesch E., Noachtar S., Benecke R., Classen J. Differential effects on motorcortical inhibition induced by blockade of GABA uptake in humans. J. Physiol. (Lond.) 1999, 517(2):591-597.
268. Wolf R.C., Gron G., Sambataro F., Vasic N., Wolf N.D., Thomann P.A., et al. Magnetic resonance perfusion imaging of resting-state cerebral blood flow in preclinical Huntington's disease. J. Cereb. Blood Flow Metab. 2011, 31(9):1908-1918.
269. Wolf R.C., Sambataro F., Vasic N., Schönfeldt-Lecuona C., Ecker D., Landwehrmeyer B. Aberrant connectivity of lateral prefrontal networks in presymptomatic Huntington's disease. Exp. Neurol. 2008, 213(1):137-144.
270. Wolf R.C., Sambataro F., Vasic N., Wolf N.D., Thomann P.A., Saft C., et al. Default-mode network changes in preclinical Huntington's disease. Exp. Neurol. 2012, 237(1):191-198.
271. Wolf R.C., Vasic N., Schönfeldt-Lecuona C., Ecker D., Landwehrmeyer G.B. Cortical dysfunction in patients with Huntington's disease during working memory performance. Hum. Brain Mapp. 2009, 30(1):327-339.
272. Wu A., Fregni F., Simon D., Deblieck C., Pascual-Leone A. Noninvasive brain stimulation for Parkinson's disease and dystonia. Neurotherapeutics 2008, 5(2):345-361.
273. Yozbatiran N., Alonso-Alonso M., See J., Demirtas-Tatlidede A., Luu D., Motiwala R.R., et al. Safety and behavioral effects of high-frequency repetitive transcranial magnetic stimulation in stroke. Stroke 2009, 40(1):309-312.
274. Ziemann U. TMS and drugs. Clin. Neurophysiol. 2004, 115(8):1717-1729.
275. Ziemann U. Transcranial magnetic stimulation at the interface with other techniques: a powerful tool for studying the human cortex. Neuroscientist 2011, 17(4):368-381.
276. Ziemann U., Lönnecker S., Steinhoff B.J., Paulus W. Effects of antiepileptic drugs on motor cortex excitability in humans: a transcranial magnetic stimulation study. Ann. Neurol. 1996, 40(3):367-378.
277. Zimbelman J.L., Paulsen J.S., Mikos A., Reynolds N.C., Hoffmann R.G., Rao S.M. fMRI detection of early neural dysfunction in preclinical Huntington's disease. J. Int. Neuropsychol. Soc. 2007, 13(05):758-769.
278. Zuccato C., Ciammola A., Rigamonti D., Leavitt B.R., Goffredo D., Conti L., et al. Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease. Science 2001, 293(5529):493-498.